1.) Leitch D, Barrans SL, Jack AS, Owen RG. 2003. Dysregulation of apoptosis in Waldenstrom's macroglobulinemia does not involve nuclear factor kappa B activation. Semin Oncol. Apr;30(2):161-4.2.) Stjernholm-Vladic Y, Stygar D, Mansson C, Masironi B, Akerberg S, Wang H, Ekman-Ordeberg G, and Sahlin L. 2004. Factors involved in the inflammatory events of cervical ripening in humans. Reproductive Biology & Endocrinology 2:74.3.) Lee KW, Lee Y, Kwon HJ and Kim DS. 2005. Sp1-associated activation of macrophage inflammatory protein-2 promoter by CpG-oligodeoxynucleotide and lipopolysaccharide. Cell and Molecular Life Sciences 62:188-198. 4.)Joo SS, Won TJ, Lee do I. Potential role of ursodeoxycholic acid in suppression of nuclear factor kappa B in microglial cell line (BV-2). Arch Pharm Res. 2004 Sep;27(9):954-60. 5.) Popov Y, Patsenker E, Bauer M, Niedobitek E, Schulze-Krebs A, Schuppan D. 2006. Halofuginone induces matrix metalloproteinases in rat hepatic stellate cells via activation of p38 and NFkappaB. J Biol Chem. 281(22):15090-8.6.) Longpré F, Garneau P, Christen Y, Ramassamy C. 2006. Protection by EGb 761 against beta-amyloid-induced neurotoxicity: involvement of NF-kappaB, SIRT1, and MAPKs pathways and inhibition of amyloid fibril formation. Free Radic Biol Med. Dec 15;41(12):1781-94. 7.) Kang HB, Kim YE, Kwon HJ, Sok DE, Lee Y. 2007. Enhancement of NF-kappaB expression and activity upon differentiation of human embryonic stem cell line SNUhES3. Stem Cells Dev. 2007 Aug;16(4):615-23.8.) Lee KW, Lee Y, Kim DS, Kwon HJ. 2006. Direct role of NF-kappaB activation in Toll-like receptor-triggered HLA-DRA expression. Eur J Immunol. May;36(5):1254-66.9.) Fan Z, Söder S, Oehler S, Fundel K, Aigner T. 2007. Activation of interleukin-1 signaling cascades in normal and osteoarthritic articular cartilage. Am J Pathol. Sep;171(3):938-46.
1. Lentsch AB, Ward PA. The NFkappaBb/IkappaB system in acute inflammation. Arch Immunol Ther Exp (Warsz). 48(2): 59-63. 2. Hatada EN, Krappmann D, Scheidereit C. NF-kappaB and the innate immune response. Curr Opin Immunol. 2000 Feb; 12(1): 52-8 3. Ho E, Bray TM. Antioxidants, NFkappaB activation, and diabetogenesis. Proc Soc Exp Biol Med. 1999 Dec; 222(3): 205-13.4. Valen G, Yan ZQ, Hansson GK. Nuclear factor kappa-B and the heart. J Am Coll Cardiol. 2001 Aug; 38(2): 307-14.5. Chen FE, Kempiak S, Huang DB, Phelps C, Ghosh G. Construction, expression, purification and functional analysis of recombinant NFkappaB p50/p65 heterodimer. Protein Eng. 1999 May; 12(5): 423-8.6. Sengchanthalangsy LL, Datta S, Huang DB, Anderson E, Braswell EH, Ghosh G. Characterization of the dimer interface of transcription factor NFkappaB p50 homodimer. J Mol Biol. 1999 Jun 18; 289(4): 1029-40.7. Huang DB, Huxford T, Chen YQ, Ghosh G. The role of DNA in the mechanism of NFkappaB dimer formation: crystal structures of the dimerization domains of the p50 and p65 subunits. Structure. 1997 Nov 15; 5(11): 1427-36.8. Magnani M, Crinelli R, Bianchi M, Antonelli A. The ubiquitin-dependent proteolytic system and other potential targets for the modulation of nuclear factor-kB (NF-kB). Curr Drug Targets. 2000 Dec; 1(4): 387-99.